Clinical Pharmacist Involved in the Treatment of Pneumocystis carinii Pneumonia: A Case Report
Fangyuan Lai,Xiuqiong Huang,Jiao Peng,Nannan He,Zhongqiang Cao,Yuhui Wu,Wei Li,Zebin Chen,Xuejuan Li
DOI: https://doi.org/10.2147/idr.s477404
2024-11-13
Infection and Drug Resistance
Abstract:Fangyuan Lai, 1, &ast Xiuqiong Huang, 2, &ast Jiao Peng, 3 Nannan He, 4 Zhongqiang Cao, 1 Yuhui Wu, 4 Wei Li, 5 Zebin Chen, 1 Xuejuan Li 1 1 Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, People's Republic of China; 2 Department of Pharmacy, The First People's Hospital of Zhaoqing, Zhaoqing, People's Republic of China; 3 Department of Pharmacy, Peking University Shenzhen Hospital, Shenzhen, People's Republic of China; 4 Department of Pediatric Intensive Care Unit, Shenzhen Children's Hospital, Shenzhen, People's Republic of China; 5 Department of Pharmacy, The Third People's Hospital of Shenzhen, Shenzhen, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xuejuan Li, Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, People's Republic of China, Email Objective: The first-line treatment for severe Pneumocystis carinii pneumonia (PCP) is trimethoprim-sulfamethoxazole (TMP/SMZ). Here, we report a case involving 6-month-old child with a PCP infection, highlighting the role of clinical pharmacists in providing individualized pharmaceutical care and guidance through the process of therapeutic drug monitoring (TDM). Methods: The clinical pharmacist monitored the concentration of TMP/SMZ in the serum, urine and sputum of a 6-month-old child with PCP infection. To improve the serum levels of TMP/SMZ, the dose of TMP/SMZ was increased, while infusions of other medications were reduced to decrease the rate of drug excretion. Additionally, the patient received other supportive medications to enhance clinical therapeutic efficacy. Results: Clinical pharmacists observed that, despite administration of a sufficient dose of TMP/SMZ, plasma concentration of TMP/SMZ remained below the therapeutic window, while urine concentrations were extremely high. This phenomenon was attributed to Augmented Renal Clearance (ARC), often seen in critically ill patients and associated with increased renal clearance. Throughout treatment, the concentrations of SMZ remained below the minimum effective concentration, while the concentrations of TMP fell within the effective target range. However, sufficient therapeutic effects were ultimately achieved and observed in the patient, likely due to improved drug distribution in lung tissue (sputum) and the patient's recovering immune functions. Finally, thanks to individualized pharmaceutical care from clinical pharmacists and the combined efforts of clinicians, the patient was discharged after 58 days of hospitalization. Conclusion: Throughout treatment, the clinical pharmacist played a vital role in optimizing the treatment plan based on the serum, urine and sputum concentrations of TMP/SMZ and providing pharmaceutical care to ensure a safe, rational and effective medications in children. Individualized dose adjustments, particularly high-dose TMP/SMZ guided by TDM, can significantly enhance the management of PCP in pediatric patients and support clinical pharmacists in delivering individualized pharmaceutical care. Keywords: Pneumocystis carinii pneumonia, trimethoprim/sulfamethoxazole, therapeutic drug monitoring, plasma drug concentration Pneumocystis carinii is widely distributed in nature, inhabiting the respiratory tracts of humans and a variety of mammals. While most are inapparent infections, this organism can cause opportunistic infections in individuals with immunodeficiency or compromised immune functions, leading to severe Pneumocystis carinii pneumonia (PCP). 1 A recent study also estimated that Pneumocystis carinii pneumonia (PCP) affects approximately 505,000 people, with 214,000 deaths (42.4%) across more than 120 countries. 2 Some studies indicate that PCP has a high mortality rate regardless of co-infection with human immunodeficiency virus (HIV), with mortality rate in non-HIV patients exceeding 50%. 3–5 The first-line treatment for PCP is trimethoprim-sulfamethoxazole (TMP/SMZ). 6,7 However, high mortality rates and significant incidence of adverse drug reactions (ADRs) amongst other clinical challenges remain common despite TMP/SMZ therapy. 8,9 Recent studies showed an increase in TMP/SMZ use in pediatric populations, correlating with a rise in treatment-related ADRs. 10,11 Therefore, achieving precise administration of TMP/SMZ with adequate drug concentration at the site of infection while minimizing the risk of related ADRs remains a key clinical priority. Early clinical trial data indicated that higher exposure levels (mean C max -Abstract Truncated-
pharmacology & pharmacy,infectious diseases